{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T16:00:10Z","timestamp":1787932810863,"version":"build-2784847793"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T00:00:00Z","timestamp":1775952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01491-1","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T23:44:22Z","timestamp":1775951062000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CMML2AML: machine-learning discovery of co-mutations and specific single mutations predictive of blast transformation in chronic myelomonocytic leukemia"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9979-7923","authenticated-orcid":false,"given":"Saubia","family":"Fathima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6956-3341","authenticated-orcid":false,"given":"Lior","family":"Rokach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Yousuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyansh","family":"Faldu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Alsugair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1221-8854","authenticated-orcid":false,"given":"Clifford","family":"Csizmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merry","family":"Nakhleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2458-9887","authenticated-orcid":false,"given":"Abhishek A.","family":"Mangaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2404-8829","authenticated-orcid":false,"given":"Luca","family":"Lanino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Campagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Maggioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noushin","family":"Farnoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0355-6368","authenticated-orcid":false,"given":"Raajit","family":"Rampal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5439-0778","authenticated-orcid":false,"given":"Kaaren K.","family":"Reichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6116-8163","authenticated-orcid":false,"given":"Rong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-6172","authenticated-orcid":false,"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6998-662X","authenticated-orcid":false,"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo G.","family":"Della Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-3821","authenticated-orcid":false,"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,12]]},"reference":[{"key":"1491_CR1","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u20131719.","journal-title":"Leukemia"},{"key":"1491_CR2","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u20131228.","journal-title":"Blood"},{"key":"1491_CR3","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/ajh.27271","volume":"99","author":"MM Patnaik","year":"2024","unstructured":"Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management. Am J Hematol. 2024;99:1142\u20131165.","journal-title":"Am J Hematol"},{"key":"1491_CR4","doi-asserted-by":"crossref","unstructured":"Tefferi A, Fathima S, Abdelmagid M, Alsugair A, Aperna F, Rezasoltani M, et al. BLAST: a globally applicable and molecularly versatile survival model for chronic myelomonocytic leukemia. Blood. 2025;146:874-886.","DOI":"10.1182\/blood.2024027170"},{"key":"1491_CR5","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/ajh.23962","volume":"90","author":"MM Patnaik","year":"2015","unstructured":"Patnaik MM, Wassie EA, Lasho TL, Hanson CA, Ketterling R, Tefferi A. Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome. Am J Hematol. 2015;90:411\u2013416.","journal-title":"Am J Hematol"},{"key":"1491_CR6","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","volume":"128","author":"C Elena","year":"2016","unstructured":"Elena C, Gall\u00ec A, Such E, Meggendorfer M, Germing U, Rizzo E, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128:1408\u20131417.","journal-title":"Blood"},{"key":"1491_CR7","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/leu.2013.88","volume":"27","author":"MM Patnaik","year":"2013","unstructured":"Patnaik MM, Padron E, LaBorde RR, Lasho TL, Finke CM, Hanson CA, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013;27:1504\u20131510.","journal-title":"Leukemia"},{"key":"1491_CR8","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1038\/leu.2014.125","volume":"28","author":"MM Patnaik","year":"2014","unstructured":"Patnaik MM, Itzykson R, Lasho T, Kosmider O, Finke C, Hanson C, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia. 2014;28:2206\u20132212.","journal-title":"Leukemia"},{"key":"1491_CR9","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s41379-019-0359-9","volume":"33","author":"R He","year":"2020","unstructured":"He R, Devine DJ, Tu ZJ, Mai M, Chen D, Nguyen PL, et al. Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis. Mod Pathol. 2020;33:334\u2013343.","journal-title":"Mod Pathol"},{"key":"1491_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/bloodadvances.2024013648","volume":"9","author":"S Casta\u00f1o-D\u00edez","year":"2025","unstructured":"Casta\u00f1o-D\u00edez S, L\u00f3pez-Guerra M, Zugasti I, Calvo X, Schulz FI, Avenda\u00f1o A, et al. AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular. Blood Adv. 2025;9:39\u201353.","journal-title":"Blood Adv"},{"key":"1491_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201324.","journal-title":"Genet Med"},{"key":"1491_CR12","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s40291-021-00540-8","volume":"25","author":"N Mehta","year":"2021","unstructured":"Mehta N, He R, Viswanatha DS. Internal standardization of the interpretation and reporting of sequence variants in hematologic neoplasms. Mol Diagn Ther. 2021;25:517\u2013526.","journal-title":"Mol Diagn Ther"},{"key":"1491_CR13","first-page":"225","volume":"161","author":"J McGowan-Jordan","year":"2020","unstructured":"McGowan-Jordan J, Hastings R, Moore S. ISCN 2020: an international system for human cytogenomic nomenclature (2020) Cytogenet. Genome Res. 2020;161:225\u2013226.","journal-title":"Genome Res"},{"key":"1491_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1046\/j.1365-2141.2002.03552.x","volume":"118","author":"N Kr\u00f6ger","year":"2002","unstructured":"Kr\u00f6ger N, Zabelina T, Guardiola P, Runde V, Sierra J, Van Biezen A, et al. Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2002;118:67\u201373.","journal-title":"Br J Haematol"},{"key":"1491_CR15","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1182\/bloodadvances.2020003600","volume":"5","author":"N Gagelmann","year":"2021","unstructured":"Gagelmann N, Badbaran A, Beelen DW, Salit RB, St\u00f6lzel F, Rautenberg C, et al. A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation. Blood Adv. 2021;5:1760\u20131769.","journal-title":"Blood Adv"},{"key":"1491_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00387-y","volume":"10","author":"P Pophali","year":"2020","unstructured":"Pophali P, Matin A, Mangaonkar AA, Carr R, Binder M, Al-Kali A, et al. Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia. Blood Cancer J. 2020;10:121.","journal-title":"Blood Cancer J"},{"key":"1491_CR17","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1038\/s41375-021-01278-2","volume":"35","author":"SA Carratt","year":"2021","unstructured":"Carratt SA, Braun TP, Coblentz C, Schonrock Z, Callahan R, Curtiss BM, et al. Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia. Leukemia. 2021;35:3594\u20133599.","journal-title":"Leukemia"},{"key":"1491_CR18","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-019-0789-3","volume":"12","author":"R Bera","year":"2019","unstructured":"Bera R, Chiu MC, Huang YJ, Lin TH, Kuo MC, Shih LY. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia. J Hematol Oncol. 2019;12:104.","journal-title":"J Hematol Oncol"},{"key":"1491_CR19","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41375-024-02190-1","volume":"38","author":"G Montalban-Bravo","year":"2024","unstructured":"Montalban-Bravo G, Rodriguez-Sevilla JJ, Swanson DM, Kanagal-Shamanna R, Hammond D, Chien K, et al. Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia. Leukemia. 2024;38:1178\u20131181.","journal-title":"Leukemia"},{"key":"1491_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.113","volume":"6","author":"MM Patnaik","year":"2016","unstructured":"Patnaik MM, Lasho TL, Vijayvargiya P, Finke CM, Hanson CA, Ketterling RP, et al. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. Blood Cancer J. 2016;6:e385.","journal-title":"Blood Cancer J"},{"key":"1491_CR21","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/16078454.2021.1958486","volume":"27","author":"W Zhao","year":"2022","unstructured":"Zhao W, Zhang C, Li Y, Li Y, Liu Y, Sun X, et al. The prognostic value of the interaction between ASXL1 and TET2 gene mutations in patients with chronic myelomonocytic leukemia: a meta-analysis. Hematology. 2022;27:367\u2013378.","journal-title":"Hematology"},{"key":"1491_CR22","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1182\/blood.2021012519","volume":"139","author":"X You","year":"2022","unstructured":"You X, Liu F, Binder M, Vedder A, Lasho T, Wen Z, et al. Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation. Blood. 2022;139:1066\u20131079.","journal-title":"Blood"},{"key":"1491_CR23","unstructured":"Noushin Farnoud KM, Guglielmelli P, et al. Identification of ultra high-risk genotypes for progression to blast phase disease redefines molecular-based stratification of myelofibrosis. European Hematology Association, EHA Library, 2025;4160895:PS1820."},{"key":"1491_CR24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-019-1618-0","volume":"574","author":"A Yoshimi","year":"2019","unstructured":"Yoshimi A, Lin K-T, Wiseman DH, Rahman MA, Pastore A, Wang B, et al. Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis. Nature. 2019;574:273\u2013277.","journal-title":"Nature"},{"key":"1491_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/ejh.12549","volume":"96","author":"J Peng","year":"2016","unstructured":"Peng J, Zuo Z, Fu B, Oki Y, Tang G, Goswami M, et al. Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation. Eur J Haematol. 2016;96:65\u201371.","journal-title":"Eur J Haematol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01491-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01491-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01491-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T01:57:57Z","timestamp":1779069477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01491-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,12]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1491"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01491-1","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,12]]},"assertion":[{"value":"14 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SF: Nothing to disclose; LR: Nothing to disclose; MY: Nothing to disclose; PF: Nothing to disclose; AA: Nothing to disclose; CC: Nothing to disclose; MN: Nothing to disclose; AAM: Research funding from Novartis, BMS, Solu Therapeutics and Sanofi; AP: Nothing to disclose; LL: Nothing to disclose; AC: Nothing to disclose; GM: Nothing to disclose; NF: Nothing to disclose; RR: Honoraria Incyte Corp.; MGDP: Nothing to disclose; NG: Advisory board to DISC Medicine and Agios; MMP: Research funding from Kura Oncology, Stemline therapeutics, Epigenetix, Solutherapeutics, Polaris and has served on the advisory board for AstraZeneca and SOBI pharmaceuticals, AT: Nothing to disclose; AT and NG are members of the editorial board for BCJ.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board of the Mayo Clinic (IRB protocol number: 12-003574). All methods were performed in accordance with the Declaration of Helsinki, the relevant guidelines, and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"76"}}